Rhode Island Multistate Pharmacy Jurisprudence (MPJE) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Prepare for the Rhode Island Multistate Pharmacy Jurisprudence Exam with tailored quizzes and in-depth content review, featuring multiple choice questions, clear explanations, and practical study tips. Enhance your readiness for the exam!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is the maximum dosage unit for dihydrocodeine in Schedule III?

15 mg
25 mg
90 mg
50 mg

The correct answer is: 15 mg

The maximum dosage unit for dihydrocodeine in Schedule III is indeed 15 mg. According to federal regulations, dihydrocodeine is classified as a controlled substance, and its regulation under Schedule III includes specific limits on the allowable amounts per dosage unit. This restriction is designed to balance the medical utility of the medication for pain relief and cough suppression while minimizing the potential for abuse and addiction. In the context of pharmacological regulation, maintaining a threshold such as 15 mg per dosage unit helps to ensure that the drug is prescribed and utilized appropriately. This is particularly important for substances that could lead to dependency or misuse, as dihydrocodeine is an opioid and can have similar effects as other opioids in terms of addiction potential. Ensuring strict adherence to these dosage unit regulations is a critical aspect of pharmacy law and helps maintain the integrity of medicinal drug use while protecting public health. The other options present dosage units that exceed this maximum limit, positioning them outside the legal framework established for dihydrocodeine in Schedule III. Understanding these limits is essential for compliance with pharmacy laws and for the safety of patients.